Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.47 ▼ -0.05
(-3.29%)
MKT CAP: $444.4M • VOL: 821.2K
52W L $1 52W H $3
ROARABLE / RQD
D • 44/100
PIOTROSKI
1 / 9
PROK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$165.0M | -$183.7M | -$151.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$69.0M | -$61.2M | -$35.5M |
| EBITDA (Normalized) | -$152.9M | -$160.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$120.1M | -$126.4M | -$90.1M |
| Capital Expenditures (CapEx) | $15.2M | $29.5M | — |
| Free Cash Flow (FCF) | -$135.3M | -$155.9M | -$90.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $108.5M | $99.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$1.01B | -$995.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PROK.